Pei-Hsin Kuo1, Shi-Rui Gan2, Jie Wang3, Raymond Y Lo4, Karla P Figueroa5, Darya Tomishon6, Stefan M Pulst5, Susan Perlman7, George Wilmot8, Christopher M Gomez9, Jeremy D Schmahmann10, Henry Paulson11, Vikram G Shakkottai11, Sarah H Ying12, Theresa Zesiewicz13, Khalaf Bushara14, Michael D Geschwind15, Guangbin Xia16, S H Subramony17, Tetsuo Ashizawa18, Sheng-Han Kuo19. 1. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan. 2. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, Institute of Neurology, First Affiliated Hospital of Fujian Medical University, Fujian Key Laboratory of Molecular Neurology, Fuzhou, China. 3. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, Jiangsu, China. 4. Department of Neurology, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan. 5. Department of Neurology, University of Utah, Salt Lake City, UT, USA. 6. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. 7. Department of Neurology, University of California, Los Angeles, CA, USA. 8. Department of Neurology, Emory University, Atlanta, GA, USA. 9. Department of Neurology, University of Chicago, Chicago, IL, USA. 10. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 11. Department of Neurology, University of Michigan, Ann Arbor, MI, USA. 12. Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. 13. Department of Neurology, University of South Florida, Tampa, FL, USA. 14. Department of Neurology, University of Minnesota, Minneapolis, MN, USA. 15. Department of Neurology, University of California, San Francisco, USA. 16. Department of Neurology, University of New Mexico, Albuquerque, NM, USA. 17. Department of Neurology, McKnight Brain Institute, University of Florida, Gainsville, FL, USA. 18. Houston Methodist Research Institute, Houston, TX, USA. 19. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address: sk3295@columbia.edu.
Abstract
BACKGROUND: Dystonia is a common feature in spinocerebellar ataxias (SCAs). Whether the presence of dystonia is associated with different rate of ataxia progression is not known. OBJECTIVES: To study clinical characteristics and ataxia progression in SCAs with and without dystonia. METHODS: We studied 334 participants with SCA 1, 2, 3 and 6 from the Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) and compared the clinical characteristics of SCAs with and without dystonia. We repeatedly measured ataxia progression by the Scale for Assessment and Rating of Ataxia every 6 months for 2 years. Regression models were employed to study the association between dystonia and ataxia progression after adjusting for age, sex and pathological CAG repeats. We used logistic regression to analyze the impact of different repeat expansion genes on dystonia in SCAs. RESULTS: Dystonia was most commonly observed in SCA3, followed by SCA2, SCA1, and SCA6. Dystonia was associated with longer CAG repeats in SCA3. The CAG repeat number in TBP normal alleles appeared to modify the presence of dystonia in SCA1. The presence of dystonia was associated with higher SARA scores in SCA1, 2, and 3. Although relatively rare in SCA6, the presence of dystonia was associated with slower progression of ataxia. CONCLUSIONS: The presence of dystonia is associated with greater severity of ataxia in SCA1, 2, and 3, but predictive of a slower progression in SCA6. Complex genetic interactions among repeat expansion genes can lead to diverse clinical symptoms and progression in SCAs.
BACKGROUND:Dystonia is a common feature in spinocerebellar ataxias (SCAs). Whether the presence of dystonia is associated with different rate of ataxia progression is not known. OBJECTIVES: To study clinical characteristics and ataxia progression in SCAs with and without dystonia. METHODS: We studied 334 participants with SCA 1, 2, 3 and 6 from the Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) and compared the clinical characteristics of SCAs with and without dystonia. We repeatedly measured ataxia progression by the Scale for Assessment and Rating of Ataxia every 6 months for 2 years. Regression models were employed to study the association between dystonia and ataxia progression after adjusting for age, sex and pathological CAG repeats. We used logistic regression to analyze the impact of different repeat expansion genes on dystonia in SCAs. RESULTS:Dystonia was most commonly observed in SCA3, followed by SCA2, SCA1, and SCA6. Dystonia was associated with longer CAG repeats in SCA3. The CAG repeat number in TBP normal alleles appeared to modify the presence of dystonia in SCA1. The presence of dystonia was associated with higher SARA scores in SCA1, 2, and 3. Although relatively rare in SCA6, the presence of dystonia was associated with slower progression of ataxia. CONCLUSIONS: The presence of dystonia is associated with greater severity of ataxia in SCA1, 2, and 3, but predictive of a slower progression in SCA6. Complex genetic interactions among repeat expansion genes can lead to diverse clinical symptoms and progression in SCAs.
Authors: Heike Jacobi; Sophie Tezenas du Montcel; Peter Bauer; Paola Giunti; Arron Cook; Robyn Labrum; Michael H Parkinson; Alexandra Durr; Alexis Brice; Perrine Charles; Cecilia Marelli; Caterina Mariotti; Lorenzo Nanetti; Marta Panzeri; Maria Rakowicz; Anna Sulek; Anna Sobanska; Tanja Schmitz-Hübsch; Ludger Schöls; Holger Hengel; Laszlo Baliko; Bela Melegh; Alessandro Filla; Antonella Antenora; Jon Infante; José Berciano; Bart P van de Warrenburg; Dagmar Timmann; Sandra Szymanski; Sylvia Boesch; Jun-Suk Kang; Massimo Pandolfo; Jörg B Schulz; Sonia Molho; Alhassane Diallo; Thomas Klockgether Journal: Lancet Neurol Date: 2015-09-13 Impact factor: 44.182
Authors: Janghoo Lim; Tong Hao; Chad Shaw; Akash J Patel; Gábor Szabó; Jean-François Rual; C Joseph Fisk; Ning Li; Alex Smolyar; David E Hill; Albert-László Barabási; Marc Vidal; Huda Y Zoghbi Journal: Cell Date: 2006-05-19 Impact factor: 41.582
Authors: Sophie Tezenas du Montcel; Alexandra Durr; Peter Bauer; Karla P Figueroa; Yaeko Ichikawa; Alessandro Brussino; Sylvie Forlani; Maria Rakowicz; Ludger Schöls; Caterina Mariotti; Bart P C van de Warrenburg; Laura Orsi; Paola Giunti; Alessandro Filla; Sandra Szymanski; Thomas Klockgether; José Berciano; Massimo Pandolfo; Sylvia Boesch; Bela Melegh; Dagmar Timmann; Paola Mandich; Agnès Camuzat; Jun Goto; Tetsuo Ashizawa; Cécile Cazeneuve; Shoji Tsuji; Stefan-M Pulst; Alfredo Brusco; Olaf Riess; Alexis Brice; Giovanni Stevanin Journal: Brain Date: 2014-06-26 Impact factor: 13.501
Authors: Georgios Koutsis; Marios Panas; George P Paraskevas; Anastasia M Bougea; Athina Kladi; Georgia Karadima; Elisabeth Kapaki Journal: Case Rep Neurol Med Date: 2014-10-02
Authors: Shi-Rui Gan; Karla P Figueroa; Hao-Ling Xu; Susan Perlman; George Wilmot; Christopher M Gomez; Jeremy Schmahmann; Henry Paulson; Vikram G Shakkottai; Sarah H Ying; Theresa Zesiewicz; Khalaf Bushara; Michael D Geschwind; Guangbin Xia; S H Subramony; Liana Rosenthal; Tetsuo Ashizawa; Stefan M Pulst; Ning Wang; Sheng-Han Kuo Journal: Parkinsonism Relat Disord Date: 2020-02-17 Impact factor: 4.891
Authors: Ruo-Yah Lai; Darya Tomishon; Karla P Figueroa; Stefan M Pulst; Susan Perlman; George Wilmot; Christopher M Gomez; Jeremy D Schmahmann; Henry Paulson; Vikram G Shakkottai; Sarah H Ying; Theresa Zesiewicz; Khalaf Bushara; Michael Geschwind; Guangbin Xia; S H Subramony; Tetsuo Ashizawa; Sheng-Han Kuo Journal: Cerebellum Date: 2019-06 Impact factor: 3.847
Authors: Jun Tian; Satya R Vemula; Jianfeng Xiao; Enza Maria Valente; Giovanni Defazio; Simona Petrucci; Angelo Fabio Gigante; Monika Rudzińska-Bar; Zbigniew K Wszolek; Kathleen D Kennelly; Ryan J Uitti; Jay A van Gerpen; Peter Hedera; Elizabeth J Trimble; Mark S LeDoux Journal: Mol Genet Genomic Med Date: 2018-05-16 Impact factor: 2.183